Vectrus, Inc. VEC 深 滬
等待開盤 10-03 09:30:00 美东时间
32.84
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 32.84
- 總市值 3.88亿
- 52周最高 52.67
- 市盈率 靜 30.27
- 換手率 0.00%
- 52周最低 30.69
- 委 比 0.00%
- 總股本 1182.67万
- 歷史最高 60.32
- 量 比 0
- 振 幅 0.00%
- 歷史最低 12.50
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新股消息 | 滨会生物递表港交所 已将BS001推进至中国黑色素瘤III期临床试验
据港交所9月30日披露，武汉滨会生物科技股份有限公司向港交所主板提交上市申请书，华泰国际、招银国际和中银国际为联席保荐人。
09-30 21:11
如何看待股债收益相关性？
本文来自格隆汇专栏：宏观fans哲，作者：芦哲、刘子博、李昌萌、潘京 核心观点 股债收益相关性是构建多资产组合前的核心考虑因素之一。假设构建一个...
09-25 08:29
快手解密AI印钞机,生成式强化学习出价,实现超过3%的广告收入提升
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：机器之心Pro） 机器之心报道 编辑：Panda、张倩 前段时间...
09-23 13:13
癌症疫苗：从预防到治疗，重塑抗癌格局的关键力量
（来源：抗体圈） 摘要：癌症疫苗作为一种创新的免疫治疗手段，正从根本上改变癌症防控的思路。它不仅在预防 HPV、HBV 相关癌症方面取得显著成效，还在非病毒性...
09-22 15:01
Nanobiotix Presents Data Showing A Favorable Safety Profile And Early Efficacy Signals In A Heavily Pre-Treated Population Whose Cancer Progressed After Multiple Prior Lines Of Therapy Including Anti-PD-1; Reports 47.4% ORR And 14.6-Month mOS In Phase 1 Study Of JNJ-1900
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D)
09-18 04:19
Veeco Announces Upcoming Investor Events
Veeco Instruments Inc. (NASDAQ: VECO) announced that its management will participate in several investor events, including the Oppenheimer 28th Annual Technology, Internet & Communications Conference on August 12, 2025; the 6th Annual Needham Virtual Semiconductor & SemiCap 1x1 Conference on August 21, 2025; the Jefferies Semiconductor, IT Hardware & Communications Technology Conference on August 26, 2025; the Evercore ISI Semiconductor, IT Hardw...
08-07 13:00
V2X, Inc. Announces Executive Leadership Transition
Jeremy Wensinger Appointed President and CEO, Succeeding Chuck Prow MCLEAN, Va., May 13, 2024 /PRNewswire/ -- V2X, Inc. (NYSE: VVX), a leading provider of global mission solutions, announced...
2024-05-13 20:00
V2X wins $190M U.S. Army Contract to Enhance Warfighter Readiness in Middle East Operations
MCLEAN, Va., Jan. 4, 2024 /PRNewswire/ -- V2X, Inc. (NYSE: VVX) was awarded a $190 million contract from the U.S. Army as part of the United States Army Central Command (USARCENT) Training a...
2024-01-04 20:00
Shawn Mural Named Senior Vice President and Chief Financial Officer at V2X
MCLEAN, Va., Oct. 2, 2023 /PRNewswire/ -- V2X, Inc. (NYSE: VVX), today announced Shawn Mural has been appointed as its Senior Vice President and Chief Financial Officer (CFO). In this role, ...
2023-10-02 19:30
